


SYRIAN ARAB REPUBLIC



Number of new cases

21 926

Number of deaths


13 848

Number of prevalent cases (5-year)

45 881


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	9 679 915	9 684 892	19 364 807
Incidence*			
Number of new cancer cases	10 179	11 747	21 926
Age-standardized incidence rate	142.7	136.9	138.6
Risk of developing cancer before the age of 75 years (cum. risk %)	14.3	13.3	13.7
Top 3 leading cancers (ranked by cases)**	Lung Prostate Leukaemia	Breast Colorectum Corpus uteri	Breast Lung Colorectum
Mortality*			
Number of cancer deaths	7 217	6 631	13 848
Age-standardized mortality rate	103.7	80.5	91.0
Risk of dying from cancer before the age of 75 years (cum. risk %)	10.5	8.1	9.3
Top 3 leading cancers (ranked by deaths)**	Lung Leukaemia Prostate	Breast Lung Colorectum	Lung Breast Colorectum
Prevalence*			
5-year prevalent cases	19 625	26 256	45 881



Top 5 most frequent cancers**

Males




Total: 10 179

Rank	Cancer site	Number of cases	Percent
1st	Lung	1 987	19.5%
2nd	Prostate	1 115	11.0%
3rd	Leukaemia	744	7.3%
4th	Colorectum	705	6.9%
5th	Brain CNS	633	6.2%
-	Others	4 995	49.1%

Number of new cases in 2022, males, all ages

Females




Total: 11 747

Rank	Cancer site	Number of cases	Percent
1st	Breast	4 114	35.0%
2nd	Colorectum	921	7.8%
3rd	Corpus uteri	704	6.0%
4th	Lung	651	5.5%
5th	Leukaemia	644	5.5%
-	Others	4 713	40.1%

Number of new cases in 2022, females, all ages

Both sexes



Total: 21 926

Rank	Cancer site	Number of cases	Percent
1st	Breast	4 114	18.8%
2nd	Lung	2 638	12.0%
3rd	Colorectum	1 626	7.4%
4th	Leukaemia	1 388	6.3%
5th	Prostate	1 115	5.1%
-	Others	11 045	50.4%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	4 114	1	18.8	5.0	1 781	2	12.9	2.3	9 974	103.0
Lung	2 638	2	12.0	2.1	2 517	1	18.2	2.0	3 795	19.6
Colorectum	1 626	3	7.4	1.1	1 092	3	7.9	0.72	3 394	17.5
Leukaemia	1 388	4	6.3	0.83	1 016	4	7.3	0.64	3 197	16.5
Prostate	1 115	5	5.1	1.7	529	9	3.8	0.62	1 886	19.5
Brain CNS	1 028	6	4.7	0.64	792	5	5.7	0.50	2 775	14.3
NHL	914	7	4.2	0.49	545	8	3.9	0.30	2 259	11.7
Thyroid	837	8	3.8	0.40	157	17	1.1	0.12	2 169	11.2
Stomach	721	9	3.3	0.50	650	6	4.7	0.44	1 074	5.6
Bladder	721	9	3.3	0.53	396	10	2.9	0.29	1 635	8.4
Corpus uteri	704	11	3.2	0.94	182	16	1.3	0.25	1 893	19.6
Pancreas	619	12	2.8	0.47	562	7	4.1	0.43	662	3.4
Ovary	462	13	2.1	0.53	294	13	2.1	0.43	1 051	10.9
Kidney	447	14	2.0	0.31	208	15	1.5	0.14	994	5.1
Larynx	427	15	1.9	0.34	272	14	2.0	0.22	968	5.0
Liver	408	16	1.9	0.29	395	11	2.9	0.28	528	2.7
Multiple myeloma	346	17	1.6	0.30	329	12	2.4	0.29	755	3.9
Hodgkin lymphoma	301	18	1.4	0.19	113	19	0.82	0.08	741	3.8
Cervix uteri	206	19	0.94	0.30	106	21	0.77	0.17	487	5.0
Testis	201	20	0.92	0.17	52	24	0.38	0.04	577	6.0
Lip, oral cavity	195	21	0.89	0.15	136	18	0.98	0.11	436	2.3
Gallbladder	132	22	0.60	0.10	108	20	0.78	0.08	180	0.93
Melanoma	130	23	0.59	0.07	44	26	0.32	0.01	321	1.7
Nasopharynx	126	24	0.57	0.05	80	23	0.58	0.03	303	1.6
Oesophagus	106	25	0.48	0.06	97	22	0.70	0.06	160	0.83
Salivary glands	83	26	0.38	0.06	52	24	0.38	0.04	204	1.1
Vulva	45	27	0.21	0.07	30	27	0.22	0.05	99	1.0
Mesothelioma	27	28	0.12	0.03	25	28	0.18	0.02	38	0.20
Kaposi sarcoma	24	29	0.11	0.02	7	31	0.05	0.00	48	0.25
Oropharynx	16	30	0.07	0.02	11	29	0.08	0.01	30	0.15
Vagina	14	31	0.06	0.02	10	30	0.07	0.01	26	0.27
Hypopharynx	7	32	0.03	0.00	6	32	0.04	0.01	10	0.05
All cancers	21 926	-	-	13.7	13 848	-	-	9.3	45 881	-
All cancers excl. NMSC	21 505	-	-	13.5	13 647	-	-	9.2	44 861	-

Data source and methods

Incidence



Country-specific data source: No data
Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

Mortality

Country-specific data source: National (WHO)
Method: National rates projected to 2022

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011–2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

